Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in Rheumatoid Arthritis

Lynk Pharmaceuticals announced positive long-term results from its pivotal Phase III trial of zemprocitinib, a selective JAK1 inhibitor, for moderate-to-severe active rheumatoid arthritis in patients with inadequate response to bDMARDs. The study demonstrated sustained improvements in disease activity and physical function through Week 76.